Key facts
- PeriVision’s last known valuation is $14.4M (Sep 2025).
- It has raised $7.8M; the latest was Later Stage VC ($3.0M) in Sep 2025.
- Notable investors include Venture Kick, Arya Ventures, Biopole, Cadfem Germany, DART Ventures — 18 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for PeriVision
- ·The full record, as it builds
Funding rounds
No funding rounds for PeriVision are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PeriVision
Developer of digital tools for eye disease diagnosis designed to improve clinic productivity, enhance diagnostic accuracy, and broaden patient access. The company offers virtual reality-based eye testing systems that use machine learning and cloud computing, enabling ophthalmologists and optometrists to diagnose and monitor conditions such as glaucoma and age-related macular degeneration more efficiently.
- Sector
- Healthcare
- HQ
- Epalinges, Switzerland
- Founded
- 2019
- Employees
- 17
- Website
- perivision.com/
- Ownership
- Privately Held (backing)
PeriVision doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PeriVision shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PeriVision in its N-PORT filings yet. We sweep new filings monthly.